newsit

Victoria University Leads the Way in Environmental Education with Autro Islas Allende

A momentous occasion unfolded today as Victoria University embarked on a groundbreaking journey towards preserving Uganda’s stunning biodiversity. A Vision for the Future In a move that resonates with innovation and dedication, the university inked a partnership deal with the globally acclaimed environmentalist and media sensation, Autro Islas Allende, to establish the Autro Islas Allende…

Read More

Breaking News: China Approves New Drug for Ros1 Inhibitor – Finally, Relief for Our Rosacea!

Oh, the Drama: AnHeart Therapeutics and Innovent Biologics Make Waves in the Biopharmaceutical World Breaking News: New York & Suzhou, China–-AnHeart Therapeutics (“AnHeart”) and Innovent Biologics, Inc. (“Innovent”) have joined forces to develop novel precision therapies for individuals battling cancer. The two powerhouse companies have officially announced their collaboration, sparking excitement and curiosity within the…

Read More

Unlocking the Power of Blarcamesine: Anavex Life Sciences Receives U.S. Patent for Revolutionary Treatment of Insomnia and Anxiety

Anavex Life Sciences Announces Grant of Its Newest U.S. Patent Expanding Anavex’s Compounds Intellectual Property Portfolio NEW YORK, Nov. 22, 2023 (GLOBE NEWSWIRE) — Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’s disease, Parkinson’s disease, Rett…

Read More

Revolutionizing Treatment: Nexcella’s CAR-T NXC-201 Receives FDA Approval for U.S. Patient Dosing

Nexcella Announces Expansion of NXC-201 Studies in Relapsed/Refractory AL Amyloidosis About NEXICART-2 Clinical Trial Nexcella, Inc. has announced the expansion of the NEXICART-2 clinical trial to U.S. sites following clearance of the Investigational New Drug (IND) application. This decision comes after positive results from the initial study involving 72 patients who were previously dosed with…

Read More